Hydralazine effectively reduced impedance after valve replacement surgery by lowering blood pressure and vascular resistance. This improved cardiac output and stroke volume, demonstrating its potential as a vasodilator in post-operative cardiac patients.
Related Concept Videos
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
Post-operative management after aortic or mitral valve replacement requires careful hemodynamic monitoring.
Vascular impedance can be elevated following cardiac valve surgery, potentially impacting cardiac performance.
Pharmacological interventions to reduce impedance are crucial for optimizing patient recovery.
Purpose of the Study:
To evaluate the efficacy of hydralazine in reducing impedance in patients undergoing aortic or mitral valve replacement.
To assess the hemodynamic effects of two different hydralazine dosages (0.25 mg/kg and 0.5 mg/kg).
To compare the responses between the two dosage groups and to baseline measurements.
Main Methods:
A randomized study involving 23 patients 1-3 hours post-valve replacement.
Patients were assigned to receive either 0.25 mg/kg or 0.5 mg/kg of hydralazine.
Hemodynamic parameters including mean arterial pressure, systemic vascular resistance, cardiac index, stroke volume index, heart rate, central venous pressure, and left atrial pressure were measured at 20, 60, and 120 minutes.
Main Results:
Hydralazine significantly decreased mean arterial pressure and systemic vascular resistance in Group 1 (0.25 mg/kg).
Cardiac index and stroke volume index significantly increased in Group 1, indicating improved cardiac output.
Group 2 (0.5 mg/kg) showed similar trends but with some differences in filling pressures and ventricular stroke work compared to Group 1.
Conclusions:
Hydralazine effectively reduces arterial impedance in patients after aortic or mitral valve replacement.
The drug selectively dilates the arterial system, leading to decreased blood pressure and vascular resistance.
These effects result in increased cardiac output and stroke volume, with acceptable filling pressures, highlighting hydralazine's therapeutic potential.